Zydus Cadila gets tentative USFDA nod for Epilepsy drug

Brivaracetam is used to treat partial-onset of seizures (epilepsy)

47

Last Updated on June 16, 2021 by The Health Master

Zydus Cadila has received tentative approval from the USFDA to market Brivaracetam Tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg (US RLD: Briviact Tablets). Brivaracetam is used to treat partial-onset of seizures (epilepsy).

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Lupin gets warning letter from USFDA for Somerset facility

Lupin gets USFDA nod for generic drug to treat HIV infection

Glenmark gets USFDA nod for Theophylline ER tablets

Zydus Cadila gets tentative USFDA nod for Osimertinib Tablets

Zydus Cadila gets USFDA nod for Fluphenazine HCL Tablets

Glenmark gets USFDA nod for Icatibant injection single-dose prefilled syringe

Application Forms: Drugs, Cosmetics and Medical Devices

WHO asks China to cooperate with probe into origins of C-19

Oxygen: Project O2 for India

Probe ordered into black marketing of Remdesivir

Lupin gets warning letter from USFDA for Somerset facility

Supreme Court refuses to waive off final exams of PG courses

Subscribe for daily free updates

Telegram
WhatsApp
Facebook
LinkedIn

Enter your email address:

Delivered by FeedBurner